Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma
Public ClinicalTrials.gov record NCT04375527. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of Combination Treatment of Binimetinib and Nivolumab for Advanced V600BRAF Wildtype Melanoma with Innate Anti-PD-1 Resistance
Study identification
- NCT ID
- NCT04375527
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Enrollment
- 3 participants
Conditions and interventions
Conditions
- Clinical Stage III Cutaneous Melanoma AJCC V8
- Clinical Stage IV Cutaneous Melanoma AJCC V8
- Locally Advanced Cutaneous Melanoma
- Metastatic Cutaneous Melanoma
- Pathologic Stage III Cutaneous Melanoma AJCC V8
- Pathologic Stage IIIA Cutaneous Melanoma AJCC V8
- Pathologic Stage IIIB Cutaneous Melanoma AJCC V8
- Pathologic Stage IIIC Cutaneous Melanoma AJCC V8
- Pathologic Stage IIID Cutaneous Melanoma AJCC V8
- Pathologic Stage IV Cutaneous Melanoma AJCC V8
- Unresectable Cutaneous Melanoma
Interventions
- Binimetinib Drug
- Nivolumab Biological
- Questionnaire Administration Other
Drug · Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2, 2020
- Primary completion
- Nov 21, 2024
- Completion
- Nov 21, 2024
- Last update posted
- Dec 3, 2024
2020 – 2024
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California at Los Angeles | Los Angeles | California | 90095 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04375527, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 3, 2024 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04375527 live on ClinicalTrials.gov.